SCHEMBL4083954

SCHEMBL4083954

c1ccc(COc2ccc3cc(-c4n[nH]c5ccc(-c6n[nH]c(CN7CCOCC7)n6)cc45)ccc3c2)nc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.51
FGFR1 P11362 1/20 0.46
PRKDC P78527 2/20 0.44
PIK3CA P42336 3/20 0.41
P2RY12 Q9H244 1/20 0.41
MAPK14 Q16539 1/20 0.40
SMO Q99835 1/20 0.40
FGFR4 P22455 1/20 0.40
JAK2 O60674 1/20 0.40
LRRK2 Q5S007 5/20 0.39
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NTRK1 P04629 1/20 0.38
FFAR1 O14842 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4079722 0.93 CSNK1D (0.60) CSNK1DFGFR1PRKDCFGFR4JAK2
SCHEMBL13812167 0.85 FGFR1 (0.48) CSNK1DFGFR1PRKDCPIK3CAP2RY12
SCHEMBL4043167 0.85 CSNK1D (0.57) CSNK1DJAK2LRRK2ALDH1A1HSD17B10
SCHEMBL13812040 0.84 CSNK1D (0.59) CSNK1DFGFR1JAK2LRRK2
SCHEMBL4084459 0.83 FGFR4 (0.45) CSNK1DFGFR1FGFR4L3MBTL1NTRK1
SCHEMBL4084969 0.83 CSNK1D (0.55) CSNK1DJAK2LRRK2ALDH1A1HSD17B10
SCHEMBL4079354 0.83 CSNK1D (0.58) CSNK1DFGFR1PIK3CAJAK2
SCHEMBL13812033 0.82 CSNK1D (0.57) CSNK1DJAK2LRRK2ALDH1A1HPGD
SCHEMBL4094402 0.81 FGFR4 (0.43) CSNK1DFGFR1MAPK14SMOFGFR4
SCHEMBL13811905 0.79 CSNK1D (0.56) CSNK1DJAK2LRRK2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 CSNK1D 702/4885FGFR1 827/4885PRKDC 492/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 CSNK1D 687/4885FGFR1 791/4885PRKDC 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.